These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 26761553)

  • 1. Bone health in cerebral palsy and introduction of a novel therapy.
    Scheinberg MA; Golmia RP; Sallum AM; Pippa MG; Cortada AP; Silva TG
    Einstein (Sao Paulo); 2015; 13(4):555-9. PubMed ID: 26761553
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Denosumab increases sublesional bone mass in osteoporotic individuals with recent spinal cord injury.
    Gifre L; Vidal J; Carrasco JL; Muxi A; Portell E; Monegal A; Guañabens N; Peris P
    Osteoporos Int; 2016 Jan; 27(1):405-10. PubMed ID: 26423406
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of denosumab on bone turnover markers in postmenopausal osteoporosis.
    Eastell R; Christiansen C; Grauer A; Kutilek S; Libanati C; McClung MR; Reid IR; Resch H; Siris E; Uebelhart D; Wang A; Weryha G; Cummings SR
    J Bone Miner Res; 2011 Mar; 26(3):530-7. PubMed ID: 20839290
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changes in serum vitamin D and PTH values using denosumab with or without bisphosphonate pre-treatment in osteoporotic patients: a short-term study.
    Nakamura Y; Kamimura M; Ikegami S; Mukaiyama K; Uchiyama S; Taguchi A; Kato H
    BMC Endocr Disord; 2015 Dec; 15():81. PubMed ID: 26666998
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term outcomes of children and adolescents who had cerebral palsy with secondary osteoporosis.
    Iwasaki T; Nonoda Y; Ishii M
    Curr Med Res Opin; 2012 May; 28(5):737-47. PubMed ID: 22126423
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Secondary osteoporosis in long-term bedridden patients with cerebral palsy.
    Iwasaki T; Takei K; Nakamura S; Hosoda N; Yokota Y; Ishii M
    Pediatr Int; 2008 Jun; 50(3):269-75. PubMed ID: 18533934
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Denosumab in treatment-naïve and pre-treated with zoledronic acid postmenopausal women with low bone mass: Effect on bone mineral density and bone turnover markers.
    Anastasilakis AD; Polyzos SA; Efstathiadou ZA; Savvidis M; Sakellariou GT; Papatheodorou A; Kokkoris P; Makras P
    Metabolism; 2015 Oct; 64(10):1291-7. PubMed ID: 26198440
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Retrospective evaluation of serum CTX levels after denosumab discontinuation in patients with or without prior exposure to bisphosphonates.
    Uebelhart B; Rizzoli R; Ferrari SL
    Osteoporos Int; 2017 Sep; 28(9):2701-2705. PubMed ID: 28540505
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy.
    Kendler DL; Roux C; Benhamou CL; Brown JP; Lillestol M; Siddhanti S; Man HS; San Martin J; Bone HG
    J Bone Miner Res; 2010 Jan; 25(1):72-81. PubMed ID: 19594293
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Denosumab for the Treatment of Mastocytosis-Related Osteoporosis: A Case Series.
    Orsolini G; Gavioli I; Tripi G; Viapiana O; Gatti D; Idolazzi L; Zanotti R; Rossini M
    Calcif Tissue Int; 2017 Jun; 100(6):595-598. PubMed ID: 28229176
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Switching of oral bisphosphonates to denosumab in chronic glucocorticoid users: a 12-month randomized controlled trial.
    Mok CC; Ho LY; Ma KM
    Bone; 2015 Jun; 75():222-8. PubMed ID: 25761434
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Denosumab in postmenopausal women with low bone mineral density.
    McClung MR; Lewiecki EM; Cohen SB; Bolognese MA; Woodson GC; Moffett AH; Peacock M; Miller PD; Lederman SN; Chesnut CH; Lain D; Kivitz AJ; Holloway DL; Zhang C; Peterson MC; Bekker PJ;
    N Engl J Med; 2006 Feb; 354(8):821-31. PubMed ID: 16495394
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Using early biomarker data to predict long-term bone mineral density: application of semi-mechanistic bone cycle model on denosumab data.
    Zheng J; van Schaick E; Wu LS; Jacqmin P; Perez Ruixo JJ
    J Pharmacokinet Pharmacodyn; 2015 Aug; 42(4):333-47. PubMed ID: 26123919
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Determination of serum bone-related minerals during denosumab treatment in osteoporosis patients with rheumatoid arthritis: Mineral change by denosumab in osteoporosis with rheumatoid arthritis.
    Suzuki T; Nakamura Y; Kato H
    Clin Nutr ESPEN; 2018 Aug; 26():53-56. PubMed ID: 29908683
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Motor impairment and skeletal mineralization in children with cerebral palsy.
    Akhter N; Khan AA; Ayyub A
    J Pak Med Assoc; 2017 Feb; 67(2):200-203. PubMed ID: 28138171
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass.
    Bone HG; Bolognese MA; Yuen CK; Kendler DL; Miller PD; Yang YC; Grazette L; San Martin J; Gallagher JC
    J Clin Endocrinol Metab; 2011 Apr; 96(4):972-80. PubMed ID: 21289258
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women.
    Bone HG; Bolognese MA; Yuen CK; Kendler DL; Wang H; Liu Y; San Martin J
    J Clin Endocrinol Metab; 2008 Jun; 93(6):2149-57. PubMed ID: 18381571
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sclerostin and DKK1 in postmenopausal osteoporosis treated with denosumab.
    Gatti D; Viapiana O; Fracassi E; Idolazzi L; Dartizio C; Povino MR; Adami S; Rossini M
    J Bone Miner Res; 2012 Nov; 27(11):2259-63. PubMed ID: 22692843
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: efficacy and safety results from a randomized open-label study.
    Roux C; Hofbauer LC; Ho PR; Wark JD; Zillikens MC; Fahrleitner-Pammer A; Hawkins F; Micaelo M; Minisola S; Papaioannou N; Stone M; Ferreira I; Siddhanti S; Wagman RB; Brown JP
    Bone; 2014 Jan; 58():48-54. PubMed ID: 24141036
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of anticonvulsant use on bone mineral density in non-ambulatory children with cerebral palsy.
    Cheng SW; Ko CH; Lee CY
    Hong Kong Med J; 2016 Jun; 22(3):242-8. PubMed ID: 27149974
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.